[go: up one dir, main page]

MX2018015082A - Derivado de fenilpropanamida y metodo de fabricacion y su aplicacion farmaceutica. - Google Patents

Derivado de fenilpropanamida y metodo de fabricacion y su aplicacion farmaceutica.

Info

Publication number
MX2018015082A
MX2018015082A MX2018015082A MX2018015082A MX2018015082A MX 2018015082 A MX2018015082 A MX 2018015082A MX 2018015082 A MX2018015082 A MX 2018015082A MX 2018015082 A MX2018015082 A MX 2018015082A MX 2018015082 A MX2018015082 A MX 2018015082A
Authority
MX
Mexico
Prior art keywords
manufacturing
derivative
pharmaceutical application
phenyl propanamide
propanamide derivative
Prior art date
Application number
MX2018015082A
Other languages
English (en)
Inventor
Wang Bin
He Feng
Chen Yang
Tao Weikang
Li Xin
Qian Wenjian
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2018015082A publication Critical patent/MX2018015082A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C07K1/062—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for alpha- or omega-carboxy functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona un derivado de fenilpropanamida como es representado por la fórmula (I), un método de fabricación del derivado, la aplicación del derivado como agonista del receptor de K-opioide (KOR) y la aplicación del derivado para fabricar un producto farmacéutico para el tratamiento y/o la prevención del dolor o una enfermedad relacionada con el dolor. (ver Fórmula).
MX2018015082A 2016-06-07 2017-06-06 Derivado de fenilpropanamida y metodo de fabricacion y su aplicacion farmaceutica. MX2018015082A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610397516 2016-06-07
PCT/CN2017/087328 WO2017211272A1 (zh) 2016-06-07 2017-06-06 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2018015082A true MX2018015082A (es) 2019-04-22

Family

ID=60578399

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015082A MX2018015082A (es) 2016-06-07 2017-06-06 Derivado de fenilpropanamida y metodo de fabricacion y su aplicacion farmaceutica.

Country Status (13)

Country Link
US (1) US20190144499A1 (es)
EP (1) EP3466962A4 (es)
JP (1) JP7120927B2 (es)
KR (1) KR102401743B1 (es)
CN (3) CN108290926B (es)
AU (1) AU2017277003B2 (es)
BR (1) BR112018074431A2 (es)
CA (1) CA3025710A1 (es)
MX (1) MX2018015082A (es)
RU (1) RU2738207C2 (es)
TW (1) TWI781938B (es)
UA (1) UA123737C2 (es)
WO (1) WO2017211272A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3025710A1 (en) * 2016-06-07 2017-12-14 Jiangsu Hengrui Medicine Co., Ltd. Phenyl propanamide derivative, and manufacturing method and pharmaceutical application thereof
EP3521301B1 (en) 2016-09-27 2024-03-06 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Polyamide compound and use thereof
MX2020005932A (es) * 2017-12-06 2020-08-24 Jiangsu Hengrui Medicine Co Sal de derivado de fenilpropionamida y su metodo de preparacion.
BR112020010429A2 (pt) * 2017-12-06 2020-11-24 Jiangsu Hengrui Medicine Co., Ltd. uso de agonista de kor em combinação com agonista de mor na preparação de fármaco para tratamento da dor
CN109879934B (zh) * 2017-12-06 2020-12-08 江苏恒瑞医药股份有限公司 一种苯基丙酰胺类衍生物的盐及其制备方法
TW202015716A (zh) 2018-05-16 2020-05-01 大陸商江蘇恆瑞醫藥股份有限公司 一種ｋｏｒ受體激動劑醫藥組成物
WO2021026492A1 (en) 2019-08-07 2021-02-11 Humanwell Pharmaceutical US Kappa opioid receptor peptide amide agonists
CN110790817A (zh) 2019-11-12 2020-02-14 成都诺和晟泰生物科技有限公司 一种多肽类化合物、制剂、药物组合物及制备方法、应用
CN113493490B (zh) * 2020-04-03 2024-03-12 成都诺和晟泰生物科技有限公司 一种合成肽酰胺类化合物及其在医药领域的用途
EP4144750A4 (en) * 2020-04-30 2024-05-22 Medshine Discovery Inc. Phenylpropionamide compound and use thereof
WO2021262173A1 (en) * 2020-06-25 2021-12-30 Humanwell Pharmaceutical US Peptides for treatment of medical disorders
FR3114739B1 (fr) * 2020-10-06 2022-08-26 Centre Nat Rech Scient Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique
WO2023160004A1 (zh) * 2022-02-25 2023-08-31 南京知和医药科技有限公司 具有镇痛活性的稠环化合物及其制备方法与用途
EP4497754A4 (en) 2022-03-23 2026-01-21 Jiangsu Nhwa Pharmaceutical Co Ltd POLYAMIDE COMPOUNDS, THEIR PREPARATION PROCESS AND MEDICAL USE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236766B2 (en) * 2006-11-10 2012-08-07 Cara Therapeutics, Inc. Uses of synthetic peptide amides
US8906859B2 (en) * 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
JP5244810B2 (ja) * 2006-11-10 2013-07-24 カラ セラピューティクス インコーポレイテッド 合成ペプチドアミド
EP2321011A1 (en) * 2008-06-25 2011-05-18 Pfizer Inc. Diaryl compounds and uses thereof
WO2010006267A2 (en) * 2008-07-11 2010-01-14 University Of Kansas Cyclic tetrapeptides
MX2011009572A (es) * 2009-03-17 2011-09-28 United Technologies Ut Ag Composiciones topicas que comprenden interleucina-1 alfa y peptidos y metodos cosmeticos de las mismas.
KR101773331B1 (ko) * 2012-03-05 2017-08-31 닥터 레디스 레보러터리즈 리미티드 카파 오피오이드 수용체(κor) 작용제인 치환된 헤테로시클릭 아세트아미드
US20150150935A1 (en) * 2012-06-05 2015-06-04 Cara Therapeutics, Inc. Peripheral kappa receptor agonists for reducing pain and inflammation
US20150272927A1 (en) * 2012-12-03 2015-10-01 University Of Washington Through Its Center For Commercialization Methods and compositions for treating vasomotor symptoms
WO2014184356A1 (en) * 2013-05-17 2014-11-20 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Perhydroquinoxaline derivatives useful as analgesics
US20160250277A1 (en) * 2013-10-28 2016-09-01 Cara Therapeutics, Inc. Peripheral kappa opioid receptor agonists for preventing, inhibiting or treating nausea and vomiting
CN105523996B (zh) * 2014-10-17 2020-03-06 江苏恒瑞医药股份有限公司 酰胺类衍生物、其制备方法及其在医药上的应用
CA3025710A1 (en) * 2016-06-07 2017-12-14 Jiangsu Hengrui Medicine Co., Ltd. Phenyl propanamide derivative, and manufacturing method and pharmaceutical application thereof

Also Published As

Publication number Publication date
RU2018145808A3 (es) 2020-07-09
RU2018145808A (ru) 2020-07-09
CN108290926B (zh) 2022-02-08
KR20190016516A (ko) 2019-02-18
CA3025710A1 (en) 2017-12-14
UA123737C2 (uk) 2021-05-26
CN114940700A (zh) 2022-08-26
RU2738207C2 (ru) 2020-12-09
TWI781938B (zh) 2022-11-01
JP2019517530A (ja) 2019-06-24
EP3466962A1 (en) 2019-04-10
TW201742858A (zh) 2017-12-16
AU2017277003B2 (en) 2021-01-07
JP7120927B2 (ja) 2022-08-17
AU2017277003A1 (en) 2018-12-13
BR112018074431A2 (pt) 2019-03-06
CN114349820A (zh) 2022-04-15
CN108290926A (zh) 2018-07-17
EP3466962A4 (en) 2020-01-08
KR102401743B1 (ko) 2022-05-24
HK1255567A1 (zh) 2019-08-23
US20190144499A1 (en) 2019-05-16
WO2017211272A1 (zh) 2017-12-14

Similar Documents

Publication Publication Date Title
MX2018015082A (es) Derivado de fenilpropanamida y metodo de fabricacion y su aplicacion farmaceutica.
IL269599B1 (en) 11, 13- modified schistosoxins for pain treatment
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
PH12019500196A1 (en) Compounds and compositions and uses thereof
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
SG11201806348PA (en) Steroid derivative fxr agonist
EP3675859A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE
MX2021015102A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
TW201613859A (en) Analogs of PRIDOPIDINE, their preparation and use
MX2020002696A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
EA202090414A1 (ru) Соединения и их применение
TN2016000489A1 (en) Carboxamide derivatives.
MY184366A (en) Pyrazines modulators of gpr6
TN2016000491A1 (en) Carboxamide derivatives.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX369451B (es) Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas.
UA117524C2 (uk) Стимулятори рослин, їх застосування та спосіб стимуляції рослин
IN2014MU00626A (es)
MX379649B (es) Derivados de azetidina para formacion de imágenes de tau.
EA038580B9 (ru) Агонист fxr, представляющий собой производное стероидов
HK40019754A (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases